Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.045
+0.015 (1.46%)
May 28, 2026, 12:55 PM EDT - Market open
Akebia Therapeutics Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Akebia Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $4.20. The average 1-year stock price forecast is 301.91% higher than the current stock price, while the lowest is $3.00 (+187.08%) and the highest is $6.00 (+474.16%).
Price Target: $4.20 (+301.91%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Akebia Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $6 | Buy | Reiterates | $6 | +474.16% | May 8, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $4 | Buy | Maintains | $4 | +282.78% | Apr 24, 2026 |
| BTIG | BTIG | Buy Maintains $4 | Buy | Maintains | $4 | +282.78% | Apr 7, 2026 |
Financial Forecast
Revenue This Year
221.95M
from 236.20M
Decreased by -6.03%
Revenue Next Year
168.89M
from 221.95M
Decreased by -23.91%
EPS This Year
-0.11
from -0.02
EPS Next Year
-0.23
from -0.11
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 280.7M | 199.3M | ||||||
| Avg | 222.0M | 168.9M | ||||||
| Low | 168.8M | 130.1M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 18.8% | -10.2% | ||||||
| Avg | -6.0% | -23.9% | ||||||
| Low | -28.6% | -41.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 0.15 | -0.05 | ||||||
| Avg | -0.11 | -0.23 | ||||||
| Low | -0.30 | -0.37 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.